CD40LG and lung carcinoma: Expressed scFv were initially analyzed using a FMAT homogenous assay and an FMAT 8100 plate reader (Figure 2A) to determine binding activity for IgM from individual early stage I lung cancer (positive control) patients and pooled normal (negative control) human serum samples.